Your browser doesn't support javascript.
loading
Identification of prognostic biomarkers for cholangiocarcinoma by combined analysis of molecular characteristics of clinical MVI subtypes and molecular subtypes.
Li, Ming-Yue; Liu, Ya-Hui; Wei, Feng; Zhang, Ping; Sun, Xiao-Dong; Wang, Meng; Du, Xiao-Hong; Ye, Jun-Feng; Qiu, Wei; Shi, Xiao-Ju; Ji, Bai; Wang, Ying-Chao; Jiang, Chao; Chai, Wen-Gang; Huang, Bo; Liu, Xing-Kai; Chen, Qing-Min; Fu, Yu; Hu, Xin-Tong; Chen, Li-Guo; He, Jia-Xue; Chai, Kai-Yuan; Gou, Zhao-Ming; Yang, Tian; Wang, Guang-Yi; Jiang, Yan-Fang; Fan, Zhong-Qi; Lv, Guo-Yue.
Afiliación
  • Li MY; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Liu YH; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Wei F; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Zhang P; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Sun XD; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Wang M; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Du XH; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Ye JF; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Qiu W; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Shi XJ; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Ji B; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Wang YC; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Jiang C; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Chai WG; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Huang B; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Liu XK; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Chen QM; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Fu Y; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Hu XT; Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Chen LG; Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • He JX; Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Chai KY; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Gou ZM; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Yang T; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Wang GY; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
  • Jiang YF; Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: yanfangjiang@jlu.edu.cn.
  • Fan ZQ; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: fanzhongqi@jlu.edu.cn.
  • Lv GY; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: lvgy@jlu.edu.cn.
Genomics ; 116(5): 110889, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38901654
ABSTRACT
Cholangiocarcinoma (CCA) is widely noted for its high degree of malignancy, rapid progression, and limited therapeutic options. This study was carried out on transcriptome data of 417 CCA samples from different anatomical locations. The effects of lipid metabolism related genes and immune related genes as CCA classifiers were compared. Key genes were derived from MVI subtypes and better molecular subtypes. Pathways such as epithelial mesenchymal transition (EMT) and cell cycle were significantly activated in MVI-positive group. CCA patients were classified into three (four) subtypes based on lipid metabolism (immune) related genes, with better prognosis observed in lipid metabolism-C1, immune-C2, and immune-C4. IPTW analysis found that the prognosis of lipid metabolism-C1 was significantly better than that of lipid metabolism-C2 + C3 before and after correction. KRT16 was finally selected as the key gene. And knockdown of KRT16 inhibited proliferation, migration and invasion of CCA cells.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Biomarcadores de Tumor / Colangiocarcinoma / Transición Epitelial-Mesenquimal Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Genomics Asunto de la revista: GENETICA Año: 2024 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Biomarcadores de Tumor / Colangiocarcinoma / Transición Epitelial-Mesenquimal Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Genomics Asunto de la revista: GENETICA Año: 2024 Tipo del documento: Article País de afiliación: China